Osteoporosis and Metabolic Bone Disease

Primary osteoporosis (mechanism = uncoupled remodeling)

• Type I (postmenopausal): estrogen withdrawal → RANKL-driven osteoclast activation with preferential loss of trabecular bone → vertebral compression and distal radius (Colles) fractures.
• Type II (senile/age-related): osteoblast senescence plus secondary hyperparathyroidism from calcium/vitamin D insufficiency → loss of both cortical and trabecular bone → femoral neck fractures.

Secondary causes (grouped by mechanism)

• Endocrine: glucocorticoid excess (endogenous Cushing or exogenous steroids — the most common drug cause; ACR guidance on glucocorticoid-induced osteoporosis applies to prolonged daily prednisone-equivalent therapy), hyperparathyroidism (cortical bone loss, subperiosteal resorption of radial phalanges), thyrotoxicosis or over-replaced levothyroxine (high turnover), hypogonadism, type 1 diabetes.
• Malabsorption/GI: celiac disease, inflammatory bowel disease, bariatric surgery, cholestatic liver disease — calcium/vitamin D malabsorption → secondary hyperparathyroidism.
• Renal: CKD–mineral and bone disorder (phosphate retention, FGF-23 excess, calcitriol deficiency) per KDIGO framing — a distinct entity from postmenopausal osteoporosis.
• Marrow/infiltrative: multiple myeloma, systemic mastocytosis, leukemia — cytokine-driven osteoclast activation.
• Drugs: glucocorticoids, aromatase inhibitors, androgen-deprivation therapy, depot medroxyprogesterone, anticonvulsants inducing vitamin D catabolism (phenytoin, phenobarbital), heparin, thiazolidinediones, proton pump inhibitors, SSRIs.
• Paget disease (for contrast): focal, disorganized osteoclast hyperactivity with compensatory woven-bone formation; associated with SQSTM1 mutations and a debated paramyxovirus trigger — a localized high-turnover disease, not generalized bone loss.

• Estrogen deficiency (primary pathophysiology in postmenopausal osteoporosis): Estrogen normally suppresses osteoclast activity and enhances osteoblast differentiation. Loss of estrogen increases RANKL (receptor activator of nuclear factor-κB ligand) expression on osteoblasts and T cells, activating RANK on osteoclast precursors. This leads to uncoupled bone turnover with excessive resorption exceeding formation.

• Aging-related changes: Progressive decline in osteoblast function and impaired differentiation from mesenchymal stem cells reduces bone formation capacity. Accumulation of senescent osteoblasts and decreased growth factor production (IGF-1, TGF-β) perpetuates negative bone balance. Increased oxidative stress and inflammation promote osteoclastogenesis while inhibiting osteoblastogenesis.

• Secondary hyperparathyroidism from calcium/vitamin D deficiency: Inadequate calcium intake or vitamin D deficiency reduces ionized serum calcium, triggering PTH secretion. PTH increases bone resorption through RANKL upregulation and enhances renal calcium reabsorption and 1,25-(OH)₂D production. Chronic PTH elevation accelerates bone loss, particularly from cortical bone.

• Micro-architectural deterioration: Loss of trabeculae (especially horizontal struts in cancellous bone) and increased cortical porosity reduce bone quality independent of BMD, compromising mechanical strength. Increased marrow adiposity and fibrosis further impair osteogenic capacity.

• Impaired fracture healing: Defective callus formation, delayed mineralization, and reduced expression of angiogenic factors prolong healing time and increase non-union risk.

• Systemic factors affecting bone homeostasis: Chronic inflammation (elevated IL-6, TNF-α, IL-1), hypogonadism (androgens also suppress osteoclasts), hyperthyroidism (increases bone turnover), glucocorticoid excess (inhibits osteoblasts, increases osteoclasts), and reduced physical activity all contribute to bone loss.

• Asymptomatic screening: Most patients are discovered through routine screening (DEXA) in asymptomatic postmenopausal women, older men, or those with risk factors. Absence of symptoms does not indicate absence of significant bone loss.

• Fragility fractures as sentinel events: Low-trauma fractures (from fall from standing height or less) are the hallmark presentation. Common sites include femoral neck (hip), vertebral bodies (thoracic/lumbar spine), and distal radius. Vertebral compression fractures may be painless or present with acute back pain.

• Chronic back pain and kyphosis: Recurrent vertebral microtrauma leads to chronic dorsal pain; multiple vertebral fractures cause progressive thoracic kyphosis ("dowager's hump"), loss of height (>3 cm loss suggestive of vertebral fracture), and functional limitation. Patients may report difficulty fitting clothes or developing abdominal protrusion.

• Hip fractures: Femoral neck fractures present with inability to bear weight, severe hip/groin pain, and external rotation/shortening of affected limb. These carry the highest morbidity with 20% excess mortality in first year post-fracture.

• Wrist/forearm fractures: Distal radius (Colles) fractures from backward fall on outstretched hand are classic presentations in postmenopausal women.

• Risk factor assessment is crucial: Thin body habitus, early menopause (<45 years), smoking, excessive alcohol, limited sun exposure, sedentary lifestyle, family history of osteoporosis/fractures, and history of falls are important contextual clues.

• Clinical pearls: Many vertebral fractures are asymptomatic and discovered incidentally on imaging. Recurrent falls warrant evaluation for secondary causes (vitamin D deficiency, neurologic disorders). Acute back pain in an elderly osteoporotic patient should raise suspicion for vertebral fracture.

• Dual-energy X-ray absorptiometry (DEXA/DXA) scan: Gold standard for BMD measurement. T-score compares patient's BMD to healthy young adult mean: T-score ≥ -1.0 (normal), -1.0 to -2.5 (low bone mass/osteopenia), < -2.5 (osteoporosis). A T-score < -2.5 with fragility fracture confirms osteoporotic fracture. Measured at lumbar spine, femoral neck, and total hip; lowest T-score determines diagnosis.

• FRAX tool: WHO fracture risk assessment calculator incorporating age, sex, BMI, history of fracture, parental hip fracture, glucocorticoid use, smoking, and alcohol use to compute 10-year probability of major osteoporotic fracture and hip fracture. Guides treatment decisions when BMD is borderline.

• Biochemical markers of bone turnover: P1NP (procollagen type 1 N-terminal propeptide) and CTX (C-terminal telopeptide of type 1 collagen) reflect formation and resorption respectively. Elevated markers may indicate high-turnover bone loss or secondary causes; useful for monitoring treatment response but not diagnostic.

• Baseline laboratory assessment: Serum calcium, phosphate, alkaline phosphatase, magnesium, 25-OH vitamin D (goal >30 ng/mL), TSH, creatinine, albumin. Consider 24-hour urine calcium to assess absorption. Elevated alkaline phosphatase may suggest secondary hyperparathyroidism or Paget disease.

• PTH level: Inappropriately normal or elevated PTH in setting of hypocalcemia/vitamin D deficiency suggests secondary hyperparathyroidism. PTH > 65 pg/mL warrants investigation for causes.

• Diagnosis of secondary causes: Serum/urine protein electrophoresis (multiple myeloma), tissue transglutaminase antibodies (celiac disease), comprehensive metabolic panel (chronic kidney disease, hyperthyroidism), 24-hour urinary cortisol (Cushing syndrome). Screen for malabsorption if clinical suspicion exists.

• Imaging considerations: Vertebral fracture assessment (VFA) on DEXA or radiographs identifies morphologic fractures. High-resolution peripheral quantitative CT (HR-pQCT) provides microarchitectural detail but is research/specialized use. Standard radiographs insensitive for early bone loss (>30% loss needed for radiographic detection).

• Important diagnostic considerations: Diagnosis cannot be made by radiograph alone; DEXA required. Do not confuse osteoporosis with osteomalacia (vitamin D deficiency causes low bone density but with impaired mineralization). Z-score (compared to age/sex/ethnicity matched controls) used if age <50 or premenopausal women; Z-score < -2.0 suggests secondary cause.

First-Line Treatments

• Bisphosphonates (most commonly prescribed): Bind to hydroxyapatite on bone surface and inhibit osteoclast-mediated resorption. Alendronate (70 mg weekly PO) or risedronate (35 mg weekly PO) are standard agents. Zoledronic acid (5 mg IV annually) preferred for patients unable to tolerate oral formulations or with poor compliance. Continue for minimum 5 years; efficacy sustained beyond 10 years

Complications of disease

• Hip fracture: the dominant driver of mortality and loss of independence; presents with a shortened, externally rotated limb and inability to bear weight. Treat as a surgical urgency — delay increases pneumonia, delirium, pressure ulcer, and venous thromboembolism risk. Perioperative PE and fat embolism are life-threatening.
• Vertebral compression fracture: acute focal back pain, height loss, progressive kyphosis with restrictive ventilatory defect and early satiety from abdominal crowding. Emergency red flags: saddle anesthesia, bowel/bladder dysfunction, or focal deficit suggest retropulsion with cord or cauda equina compression — obtain urgent MRI.
• Fracture cascade: one fragility fracture markedly raises short-term risk of the next; the "imminent risk" window justifies starting therapy before hospital discharge.
• Paget disease complications: bowing deformity and secondary osteoarthritis, pathologic fracture through woven bone, cranial nerve VIII compression causing hearing loss, spinal stenosis, high-output heart failure from hypervascular bone, and osteosarcoma — suspect when pain abruptly worsens and alkaline phosphatase rises further.

Complications of therapy

• Bisphosphonates: pill-induced esophagitis (must remain upright with water — mechanism is direct mucosal injury); acute-phase reaction after IV zoledronic acid; hypocalcemia if vitamin D is unrepleted; osteonecrosis of the jaw and atypical subtrochanteric/diaphyseal femoral fracture with long-term use — new thigh or groin pain warrants femoral imaging before it completes. Avoid in advanced renal impairment.
• Denosumab: profound RANKL blockade causes hypocalcemia (highest risk in CKD — can be an emergency with tetany or QT prolongation). Abrupt discontinuation triggers rebound bone turnover and multiple vertebral fractures; transition to a bisphosphonate rather than simply stopping.
• Romosozumab: FDA boxed warning for myocardial infarction, stroke, and cardiovascular death; avoid in patients with recent cardiovascular events.
• Teriparatide/abaloparatide: hypercalcemia and orthostatic hypotension; osteosarcoma signal from rodent studies drove historical duration limits.

• Normal labs are the point: in uncomplicated osteoporosis, serum calcium, phosphate, and alkaline phosphatase are all normal. Abnormal chemistries mean you are looking at a different metabolic bone disease — do not accept "osteoporosis" as the answer when ALP is up.
• Isolated elevated alkaline phosphatase with normal calcium and phosphate in an older adult = Paget disease of bone. Best next step is plain radiographs of the symptomatic site plus a radionuclide bone scan to map lesion extent; classic findings are cotton-wool skull, blade of grass/flame-shaped lytic front in long bones, and enlarging hat size. Nitrogen-containing bisphosphonates (IV zoledronic acid) are first-line for symptomatic disease per Endocrine Society guidance.
• Osteomalacia is the great mimic: low or low-normal calcium, low phosphate, high ALP, high PTH, and Looser zones (pseudofractures) — the defect is mineralization, not bone mass. Treat the vitamin D deficiency, not with an antiresorptive.
• A fragility fracture of the hip or spine diagnoses osteoporosis clinically, regardless of T-score — do not wait for a DEXA to start therapy.
• The screening answer: USPSTF recommends BMD testing in all women 65 and older, and in younger postmenopausal women whose fracture risk equals that of a 65-year-old; evidence is insufficient to recommend routine screening in men.
• Never start an antiresorptive before checking and repleting 25-OH vitamin D and calcium — the tested complication is symptomatic hypocalcemia, especially with denosumab in CKD.
• Denosumab has no drug holiday. Stopping it causes rebound resorption with multiple vertebral fractures; bridge with a bisphosphonate. This is the most common distractor pairing on drug-holiday questions.
• Anabolic before antiresorptive in very high-risk patients: teriparatide, abaloparatide, or romosozumab followed by a bisphosphonate or denosumab to lock in gains — anabolic gains are lost if nothing follows.